



Veracyte Announces Multiple Decipher Urologic Testing Abstracts to be Presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium

February 1, 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb. 1, 2023-- Veracyte, Inc. (Nasdaq: VCYT) today announced that six abstracts highlighting new data focused on the company's Decipher urologic cancer testing offerings will be presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium, taking place in San Francisco, Calif. and online, February 16-18, 2023.

Data being presented include new insights derived from Veracyte's Decipher Genomics Resource for Intelligent Discovery (GRID) database, which suggest potential opportunities to further personalize treatment for men with prostate cancer. Additionally, researchers will present new Decipher Prostate Genomic Classifier clinical utility data from the prospective, phase 3, randomized clinical trial, G-MINOR (Genomics in Michigan Impacting Observation or Radiation).

"Veracyte is committed to helping empower physicians with the insights they need to guide more informed, individualized treatment for patients with urologic cancers," said Elai Davicioni, Ph.D., Veracyte's medical director for Urology. "The data being presented at this year's ASCO GU Cancers Symposium advance our understanding of how our Decipher genomic tests and Decipher GRID database may help physicians further stratify risk and guide treatment decisions for their patients with prostate or bladder cancer."

Veracyte also expects additional data regarding the Decipher Prostate test to be highlighted in the following general session presentation:

Title: Treatment Combinations for Patients Starting Androgen-Deprivation Therapy: Building on Recent Victories
Presenter: Gerhardt Attard, M.D., Ph.D., University College London Cancer Institute
Date/Time: Thursday, February 16, 10:00 a.m. – 11:30 a.m. PST
Location: Level 3, Ballroom

Below are details of the abstracts that will be presented as posters at the 2023 ASCO GU Cancers Symposium in the Moscone Center in Moscone West, Level 1.

Title: Use of prostate cancer subtyping by gene expression to predict response to radiation and chemohormonal therapies.
Presenter: Adam Benjamin Weiner, M.D., UCLA
Date/Time: February 16, 2023; 11:30 a.m. PST
Abstract #: 241
Poster #: J6

Title: Determining the impact of genomic classifier testing on patient-reported quality of life after prostatectomy: Results from the G-MINOR randomized trial.
Presenter: Udit Singhal, M.D., University of Michigan
Date/Time: February 16, 2023; 11:30 a.m. PST
Abstract #: 345
Poster #: M3

Title: Comparative transcriptomic analysis of DNA-damage response and androgen receptor pathway activity between biopsy and radical prostatectomy specimens before and after pre-operative real-time MRI-guided stereotactic body radiotherapy.
Presenter: Himanshu Nagar, M.D., Weill Cornell Medicine
Date/Time: February 16, 2023; 11:30 a.m. PST
Abstract #: 375
Poster #: N13

Title: Effect of neoadjuvant stereotactic body radiation therapy (SBRT) on the immune microenvironment of high-risk localized prostate cancer in paired transcriptomic analysis of pretreatment biopsy and irradiated prostatectomy specimens.
Presenter: Ariel E. Marciscano, M.D., Weill Cornell Medical College
Date/Time: February 16, 2023; 11:30 a.m. PST
Abstract #: 371
Poster #: N9

Title: Distinct gene expression patterns identify patients who relapse after neoadjuvant pembrolizumab and radical cystectomy in the PURE-01 study.
Presenter: Moritz Reike, M.D., University of British Columbia
Date/Time: February 17, 2023; 12:30 p.m. PST
Abstract #: 549
Poster #: M12

Title: Genomic analysis from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in patients with MIBC undergoing cystectomy.

Presenter: Shilpa Gupta, M.D., Cleveland Clinic Taussig Cancer Center

Date/Time: February 17, 2023; 12:30 p.m. PST

Abstract

#: 559

Poster #: N2

About Veracyte

Veracyte is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic, and treatment decisions for some of the most challenging diseases such as thyroid, prostate, breast, bladder and lung cancers, as well as interstitial lung diseases. We help patients avoid unnecessary procedures and speed time to diagnosis and appropriate treatment. In addition to making our tests available in the U.S. through our central laboratories, our exclusive license to a best-in-class diagnostics instrument (the nCounter Analysis System) positions us to deliver our tests to patients worldwide through laboratories that can perform them locally. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to our clinical tests in and outside of the United States. Forward-looking statements can be identified by words such as: "appears," "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will," "positioned," "designed" and similar references to future periods. Examples of forward-looking statements include, among others, how Veracyte's Decipher Genomics Resource for Intelligent Discovery (GRID) database may help physicians further personalize treatment for men with prostate cancer and help physicians further stratify risk and guide treatment decisions for their patients with prostate or bladder cancer. Additional factors that may impact these forward-looking statements can be found under the caption "Risk Factors" in our Annual Report on Form 10-K filed on February 28, 2022, and our Quarterly Report on Form 10-Q to be filed for the three months ended September 30, 2022. Copies of these documents, when available, may be found in the Investors section of our website at www.investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Veracyte, the Veracyte logo and Decipher are registered trademarks of Veracyte, Inc. and its subsidiaries in the U.S. and selected countries. nCounter is the registered trademark of NanoString Technologies used by Veracyte under license.

Veracyte delivers the Decipher Prostate Genomic Classifier from its CLIA laboratories. Those tests are not CE-IVD marked and have not been cleared or approved by the FDA; their performance characteristics were determined by Veracyte and they might be considered for Research Use Only in some markets. Please contact Veracyte for confirmation. This piece is distributed purely for educational purposes and is not intended to promote or encourage any off-label use of Veracyte products.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20230201005995/en/): <https://www.businesswire.com/news/home/20230201005995/en/>

Investors:

Shayla Gorman
Director, Investor Relations
investors@veracyte.com
619-393-1545

Media:

Tracy Morris
Vice President, Global Corporate Communications
tracy.morris@veracyte.com
650-380-4413

Source: Veracyte, Inc.